Some anti-cancer agents innately undergo macropinocytosis, such as AS1411, which internalizes into various cancer cells through cell-surface nucleolin-dependent mechanisms that activate macropinocytosis only in malignant cells (Reyes-Reyes et al., 2010). This evidence concerns the gene NUCLEOLIN and cancer.